{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:31:27Z","timestamp":1786570287130,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dmd.2026.100342","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:04:57Z","timestamp":1781222697000},"page":"100342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-4841","authenticated-orcid":false,"given":"Andy","family":"Sykes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoupeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Skeete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0204-013X","authenticated-orcid":false,"given":"Stephen","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Gr\u00e4nfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Leddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bistra","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nand","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-5329","authenticated-orcid":false,"given":"Niresh","family":"Hariparsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dmd.2026.100342_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dmd.2026.100342_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International Consensus Guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"35","key":"10.1016\/j.dmd.2026.100342_bib3","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.dmd.2026.100342_bib4","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.dmd.2026.100342_bib5","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/JCO.2021.39.15_suppl.1004","article-title":"Results from VERONICA: a randomized, phase II study of second-\/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA\/MBC)","volume":"39","author":"Lindeman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.dmd.2026.100342_bib6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.dmd.2026.100342_bib7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100342_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.dmd.2026.100342_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dmd.2026.100342_bib10","article-title":"Randomized open-label study to assess relative bioavailability of different oral formulations, the effect of food on absorption and absolute bioavailability of AZD9833 (camizestrant) in postmenopausal healthy female volunteers","author":"Sykes","year":"2022","journal-title":"Poster presented at: American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2022 Annual Meeting"},{"issue":"5_suppl","key":"10.1016\/j.dmd.2026.100342_bib11","article-title":"Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor \u03b1","volume":"83","author":"Morrow","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.dmd.2026.100342_bib12","article-title":"Radiological Protection in Biomedical Research","volume":"vol 22","year":"1991","journal-title":"A report of Committee 3 adopted by the International Commission on Radiological Protection"},{"issue":"2","key":"10.1016\/j.dmd.2026.100342_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70475","article-title":"Open-label study assessing relative and absolute bioavailability of oral camizestrant formulations and food effects in healthy postmenopausal women","volume":"19","author":"Sykes","year":"2026","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2026.100342_bib14","series-title":"Blumgart's Surgery of the Liver, Biliary Tract and Pancreas","first-page":"74","article-title":"Chapter 4 \u2013 Liver blood flow: Physiology, measurement, and clinical relevance","author":"Rocha","year":"2012"},{"issue":"8","key":"10.1016\/j.dmd.2026.100342_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1124\/dmd.124.001688","article-title":"Mass balance, metabolic pathways, absolute bioavailability, and pharmacokinetics of giredestrant in healthy subjects","volume":"52","author":"Kshirsagar","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100342_bib17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/cpdd.1562","article-title":"Disposition and absolute bioavailability of oral imlunestrant in healthy women: a phase 1, open-label study","volume":"14","author":"Datta-Mannan","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dmd.2026.100342_bib18","series-title":"Paper Presented at: 14th International ISSX Meeting","article-title":"P109 - Absorption, metabolism, excretion, and pharmacokinetics of [14C]vepdegestrant in healthy adult participants","author":"Johnson","year":"2025"},{"issue":"10","key":"10.1016\/j.dmd.2026.100342_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100163","article-title":"Hydrolysis of O-, N- and N+- glucuronide metabolites in human feces","volume":"53","author":"Zhang","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100342_bib20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1208\/s12248-013-9502-6","article-title":"Meeting report: metabolites in safety testing (MIST) symposium\u2014safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?","volume":"15","author":"Gao","year":"2013","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.dmd.2026.100342_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/dmd.117.075259","article-title":"Implications for metabolite quantification by mass spectrometry in the absence of authentic standards","volume":"45","author":"Hatsis","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"16_suppl","key":"10.1016\/j.dmd.2026.100342_bib22","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2022.40.16_suppl.1032","article-title":"Serena-1: updated analyses from a phase 1 study (parts C\/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"40","author":"Oliveira","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5_Suppl","key":"10.1016\/j.dmd.2026.100342_bib23","article-title":"Abstract P3-07-28: SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"83","author":"Turner","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.dmd.2026.100342_bib24","series-title":"Poster Presented at: San Antonio Breast Cancer Symposium\u00ae (SABCS) 2024","article-title":"Results from SERENA-1 parts K\/L: a phase 1 study of the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with ribociclib in women with ER-positive, HER2 negative advanced breast cancer","author":"Ruiz-Borrego","year":"2024"},{"issue":"9_Suppl","key":"10.1016\/j.dmd.2026.100342_bib25","article-title":"Abstract PO3-19-09: SERENA-1: results from a phase 1 study (parts I\/J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+, HER2 advanced breast cancer","volume":"84","author":"Vaklavas","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100342_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03602530600952172","article-title":"What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs","volume":"39","author":"Roffey","year":"2007","journal-title":"Drug Metab Rev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:07:46Z","timestamp":1786568866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0090955626006112"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100342","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, metabolism, and excretion of single dose oral [14C]camizestrant in healthy human female participants","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100342"}}